Congratulations to our co-founder, Dr. Tak Mak for being elected as a Fellow of American Association for the Advancement of Science (AAAS) and for his lifelong and distinguished contributions to immunology and cancer research within the scientific community. #AAAS #Treadwelltx https://lnkd.in/eAA2symb
关于我们
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
- 网站
-
https://www.treadwelltx.com
Treadwell Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
US，NY，New York
Treadwell Therapeutics, Inc.员工
动态
-
We are excited to share that Treadwell Therapeutics received an orphan drug designation from the U.S. FDA to ocifisertib, a first-in-class, investigational PLK4 inhibitor for the treatment of acute myeloid leukemia (AML). We are thankful for the U.S. FDA regulatory support and the commitment from our entire team to AML patients. https://lnkd.in/gwQg5nQm #treadwelltx #leukemia #cancer #cancerresearch #oncology #biotechnology
-
-
We are proud to announce the formation of our Scientific Advisory Board. We welcome this group of prominent oncology leaders and drug developers who will help support and guide our pipeline development. https://lnkd.in/eBBwrXPA
-
-
Are you heading to #JPM2024? Our team is heading to JPM2024 in San Francisco. Please reach out to RYAN DIETZ to set up meetings to discuss partnership or investment. Look forward to connecting! Treadwell has made exciting progress and we are focused on the opportunities ahead. #JPM24 #biotech #investors
-
Treadwell Therapeutics's R&D Team attended the 65th American Society of Hematology (ASH) Annual Meeting and showcased ongoing positive data on our first-in-class inhibitor of PLK4 treating AML as well as advancing the program into key dose expansion studies in 2024. Read more about our presentation. #ASH23 #treadwellTx #treadwell #oncology #hematology #AML ?https://lnkd.in/gGqWu4bC
-
Changes are taking place at Treadwell Therapeutics to drive focus towards potential pivotal studies in 2025. https://lnkd.in/dAexZgXg
Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions
globenewswire.com